靶向CXCR1/2不能改善胰岛移植后的胰岛素分泌:一项在1型糖尿病中进行的3期双盲随机安慰剂对照试验
这项3期多中心双盲随机对照试验将胰岛同种异体移植受者按2:1随机分配至瑞帕利辛组或安慰剂组,主要终点为混合餐耐量试验中C肽曲线下面积。意向性分析显示第75天和第365天C肽AUC在两组间均无显著差异,所有次要终点亦无统计学显著差异。结论认为瑞帕利辛数据不支持CXCR1/2抑制在预防胰岛炎症介导损伤中的作用。
要点
- 瑞帕利辛组与安慰剂组在第75天和第365天C肽AUC均无显著差异。
- 所有次要终点在任何时间点两组间均无统计学显著差异。
- 使用抗胸腺细胞球蛋白诱导时,单次胰岛输注后维持胰岛素不依赖1年的受者比例在瑞帕利辛组有升高趋势但未达统计学显著。
核心结论
- 在这项首个双盲随机试验中,瑞帕利辛获得的胰岛移植数据不支持CXCR1/2抑制在预防胰岛炎症介导损伤中的作用。
研究设计与样本
- 一项3期、多中心、随机、双盲、平行分组研究(NCT01817959),在胰岛同种异体移植受者中按2:1随机分配至瑞帕利辛组或安慰剂组,两组均接受免疫抑制治疗。
- 主要终点为首次移植后第75±5天和末次移植后第365±14天混合餐耐量试验中C肽曲线下面积(AUC)。
- 次要终点包括胰岛素不依赖和血糖控制的标准指标。
主要发现
- 意向性分析显示第75天C肽AUC在瑞帕利辛组27 vs 安慰剂组18,P=0.99,无显著差异。
- 第365天C肽AUC在瑞帕利辛组24 vs 安慰剂组15,P=0.71,无显著差异。
- 所有次要变量在任何时间点两组间均无统计学显著差异。
- 亚组分析显示,在使用抗胸腺细胞球蛋白作为诱导免疫抑制时,单次胰岛输注后维持胰岛素不依赖1年的受者比例在瑞帕利辛组为26.7% vs 安慰剂组0%,P=0.09,呈升高趋势但未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients. RESEARCH DESIGN AND METHODS: A phase 3, multicenter, randomized, double-blind, parallel-assignment study (NCT01817959) was conducted in recipients of islet allotransplants randomized (2:1) to reparixin or placebo in addition to immunosuppression. Primary outcome was the area under the curve (AUC) for C-peptide during the mixed-meal tolerance test at day 75 ± 5 after the first and day 365 ± 14 after the last transplant. Secondary end points included insulin independence and standard measures of glycemic control. RESULTS: The intention-to-treat analysis did not show a significant difference in C-peptide AUC at both day 75 (27 on reparixin vs. 18 on placebo, P = 0.99) and day 365 (24 on reparixin vs. 15 on placebo, P = 0.71). There was no statistically significant difference between treatment groups at any time point for any secondary variable. Analysis of patient subsets showed a trend for a higher percentage of subjects retaining insulin independence for 1 year after a single islet infusion in patients receiving reparixin as compared with patients receiving placebo (26.7% vs. 0%, P = 0.09) when antithymocyte globulin was used as induction immunosuppression. CONCLUSIONS: In this first double-blind randomized trial, islet transplantation data obtained with reparixin do not support a role of CXCR1/2 inhibition in preventing islet inflammation-mediated damage.
引用
- Maffi P, Lundgren T, Tufveson G, et al. Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes. Diabetes Care. 2020. PMID: 32019854. doi:10.2337/dc19-1480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。